Consumers Guide JAK PsA Animation

Psoriatic arthritis

treatment has evolved over recent decades to include more targeted medications that help control the underlying cause of the condition.

2017

Welcome KAtherine

Back

approved the first Janus kinase inhibitor, or JAK inhibitor, for the treatment of psoriatic arthritis. This class of drugs is highly effective and works differently from other available treatments.

In 2017 the FDA

Back

options include disease-modifying antirheumatic drugs (DMARDs), which suppress the immune system on a broad level, and biologics, which are more targeted in how they block immune system activity.

Traditional treatment

Biologics

DMARDs

treatment options include disease-modifying antirheumatic drugs (DMARDs), which suppress the immune system on a broad level, and biologics, which are more targeted in how they block immune system activity.

Traditional

Back

They block specific pathways in the immune response thought to be involved in psoriatic arthritis. This calms the overactive immune system at the source, which in turn helps control disease activity and alleviate symptoms.

JAK inhibitors work in an even more targeted way.

Back

Replay

can be prescribed on their own or in conjunction with some other psoriatic arthritis medications to further gain control of the disease and improve quality of life.

JAK inhibitors

Biologics

DMARDs

JAK inhibitors

Biologics

DMARDs